Literature DB >> 20798478

Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia.

Kyriakie Sarafoglou1, John H Himes, Jean M Lacey, Brian C Netzel, Ravinder J Singh, Dietrich Matern.   

Abstract

BACKGROUND/AIM: periodic measurement of plasma concentrations of cortisol precursors on a clinic visit may be of limited value in patients with congenital adrenal hyperplasia because it does not reflect a patient's circadian patterns of adrenal steroid secretion. Steroid profiling in dried blood spots (DBS) may allow for more frequent and sensitive monitoring.
METHODS: we compared the agreement between 17α-hydroxyprogesterone (17-OHP) and androstenedione (D4A) levels determined from DBS samples and concurrently collected serum samples. Blood was drawn from 9 congenital adrenal hyperplasia patients every 4 h over a 24-hour period. Serum and DBS steroid levels were measured by liquid chromatography tandem mass spectrometry.
RESULTS: DBS determinations of 17-OHP overestimated corresponding serum levels (mean difference 1.67 ng/ml), and underestimated D4A serum levels (mean difference 0.84 ng/ml). However, the DBS assay yielded excellent agreement (97%) with serum 17-OHP, but did considerably poorer for D4A (31%).
CONCLUSIONS: our results indicate an excellent agreement between DBS and serum 17-OHP measurements to identify the peaks and troughs associated with an individual's circadian pattern. Larger-scale studies are required to evaluate the utility of DBS for home monitoring and to determine if more frequent monitoring leads to improved clinical outcomes. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798478      PMCID: PMC3202930          DOI: 10.1159/000315910

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  22 in total

Review 1.  Sexual function and fertility in adult females and males with congenital adrenal hyperplasia.

Authors:  J Jääskeläinen; A Tiitinen; R Voutilainen
Journal:  Horm Res       Date:  2001

2.  Characterization of the normal temporal pattern of plasma corticosteroid levels.

Authors:  D T Krieger; W Allen; F Rizzo; H P Krieger
Journal:  J Clin Endocrinol Metab       Date:  1971-02       Impact factor: 5.958

Review 3.  Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study.

Authors:  G Hargitai; J Sólyom; T Battelino; J Lebl; Z Pribilincová; R Hauspie; J Kovács; F Waldhauser; H Frisch
Journal:  Horm Res       Date:  2001

4.  Diagnosis of adrenal cortical dysfunction by liquid chromatography-tandem mass spectrometry.

Authors:  P C Kao; D A Machacek; M J Magera; J M Lacey; P Rinaldo
Journal:  Ann Clin Lab Sci       Date:  2001-04       Impact factor: 1.256

5.  Serum cortisol and 17-hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement therapy satisfactory?

Authors:  E Charmandari; D R Matthews; A Johnston; C G Brook; P C Hindmarsh
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

6.  Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry.

Authors:  Jean M Lacey; Carla Z Minutti; Mark J Magera; Angela L Tauscher; Bruno Casetta; Mark McCann; James Lymp; Si Houn Hahn; Piero Rinaldo; Dietrich Matern
Journal:  Clin Chem       Date:  2003-12-04       Impact factor: 8.327

7.  Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.

Authors:  Nike M M L Stikkelbroeck; Bep A E Van't Hof-Grootenboer; Ad R M M Hermus; Barto J Otten; Martin A Van't Hof
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

8.  Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.

Authors:  H J Van der Kamp; B J Otten; N Buitenweg; S M P F De Muinck Keizer-Schrama; W Oostdijk; M Jansen; H A Delemarre-de Waal; T Vulsma; J M Wit
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

9.  Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.

Authors:  I Manoli; Ch Kanaka-Gantenbein; A Voutetakis; M Maniati-Christidi; C Dacou-Voutetakis
Journal:  Clin Endocrinol (Oxf)       Date:  2002-11       Impact factor: 3.478

10.  Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.

Authors:  Carla Z Minutti; Jean M Lacey; Mark J Magera; Si Houn Hahn; Mark McCann; Andreas Schulze; David Cheillan; Claude Dorche; Donald H Chace; James F Lymp; Donald Zimmerman; Piero Rinaldo; Dietrich Matern
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  5 in total

1.  Unit conversions between LOINC codes.

Authors:  Ronald G Hauser; Douglas B Quine; Alex Ryder; Sheldon Campbell
Journal:  J Am Med Inform Assoc       Date:  2018-02-01       Impact factor: 4.497

Review 2.  Congenital adrenal hyperplasia: issues in diagnosis and treatment in children.

Authors:  Rajni Sharma; Anju Seth
Journal:  Indian J Pediatr       Date:  2013-11-20       Impact factor: 1.967

Review 3.  Management of congenital adrenal hyperplasia in childhood.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Mitchell E Geffner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-12       Impact factor: 3.243

4.  Clinical chemistry and dried blood spots: increasing laboratory utilization by improved understanding of quantitative challenges.

Authors:  Donald H Chace; Víctor R De Jesús; Alan R Spitzer
Journal:  Bioanalysis       Date:  2014       Impact factor: 2.681

Review 5.  Treatment and health outcomes in adults with congenital adrenal hyperplasia.

Authors:  Thang S Han; Brian R Walker; Wiebke Arlt; Richard J Ross
Journal:  Nat Rev Endocrinol       Date:  2013-12-17       Impact factor: 43.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.